Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 771716 in geographic atrophy
NCT06006585Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2023
- Primary completion
- May 2024
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of BI 771716 in geographic atrophy (GA) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Occurrence of ocular dose limiting events at Day 8 and Occurrence of drug-related adverse events at Day 112. Started Oct 2023; status: completed.
02
Drugs
BI 771716
03
Conditions
geographic atrophy (GA)
Beyond the preview
Go deeper on NCT06006585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06006585.